SGLT

SGLT Related Products (25):

Cat. No.	Product Name	Effect	Purity

HY-123797

KGA-2727	Inhibitor	98.84%
KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with K_is of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (K_i for SGLT2/K_i for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy.

HY-15409S

Empagliflozin-d₄	Inhibitor	98.40%
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2.

HY-174400

SGLT2-IN-2	Inhibitor	99.57%
SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice.

HY-14902

Tofogliflozin	Inhibitor	98.38%
Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.

HY-153113

Rongliflozin	Inhibitor
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM).

HY-166652S

Empagliflozin-d₈	Inhibitor
Empagliflozin-d₈ is the deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2.

HY-Z0437

Dapagliflozin methyl acetate	Inhibitor
Dapagliflozin methyl acetate is an orally active SGLT2 inhibitor. Dapagliflozin methyl acetate may be used in type 2 diabetes research.

HY-112807

SGLT inhibitor-1	Inhibitor
SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC₅₀s of 43 nM and 9 nM, respectively.

HY-114308

SGL5213	Inhibitor
SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC₅₀ values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment.

HY-15461S1

Ertugliflozin-d₉	Inhibitor
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.

HY-10451S2

Canagliflozin-d₆
Canagliflozin-d₆ is the deuterium labeled Canagliflozin. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.

HY-145357

SGLT1/2-IN-2	Inhibitor
SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC₅₀ = 96 nM for SGLT1 and IC₅₀ = 1.3 nM for SGLT2).

HY-117075

BI-44847	Inhibitor
BI-44847 is a selective and orally active SGLT2 inhibitor. BI-44847 can increase UGE and decrease HbA1c levels. BI-44847 shows improvement in fasting and fed glucose levels. BI-44847 can be studied in research on type 2 diabetes mellitus (T2DM).

HY-17638A

Mizagliflozin (sebacate)	Inhibitor
Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models.

HY-15516R

Sotagliflozin (Standard)	Inhibitor
Sotagliflozin (Standard) is the analytical standard of Sotagliflozin. This product is intended for research and analytical applications. Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

HY-101782R

HSK0935 (Standard)	Inhibitor
HSK0935 (Standard) is the analytical standard of HSK0935 (HY-101782). This product is intended for research and analytical applications. HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC₅₀ of 1.3 nM. Antihyperglycemic activities.

HY-109018BR

Velagliflozin proline hydrate (Standard)	Inhibitor
Velagliflozin proline hydrate (Standard) is the analytical standard of Velagliflozin (proline hydrate) (HY-109018B). This product is intended for research and analytical applications. Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.

HY-I1120R

SGLT2-IN-1 (Standard)	Inhibitor
SGLT2-IN-1 (standard) is the analytical standard for SGLT2-IN-1. This product is used for research and analytical applications. SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC₅₀ of 33 nM in CHO cells transfected with human SGLT2. SGLT2-IN-1 is selective for SGLT2 over SGLT1. SGLT2-IN-1 is an active metabolite of dapagliflozinactive metabolite of dapagliflozin.

HY-15461S

Ertugliflozin-d₅
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.

HY-166548S

Remogliflozin etabonate-d₇	Inhibitor
Remogliflozin etabonate-d₇ (GSK189075-d₇) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.

Name
Email *

	Sorry, but the email address you supplied was invalid.